Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of Zimura (avacincaptad pegol) in autosomal recessive Stargardt disease
2017-004783-35Phase 2Active
- Sponsor
- IVERIC bio
- Start
- Jan 2018
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avacincaptad pegol in Fundus Flavimaculatus (FF) (2 arms), sponsored by IVERIC bio. Started Jan 2018; status: active.
02
Drugs
avacincaptad pegol
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2017-004783-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004783-35.